FDA OKs Novartis' doublet therapy for type of thyroid cancer

|About: Novartis AG (NVS)|By:, SA News Editor

The FDA approves Novartis' (NVS +0.4%) TAFINLAR (dabrafenib) + MEKINIST (trametinib) for the treatment of unresectable or metastatic anaplastic thyroid cancer that is BRAF V600E mutation-positive.

It was previously approved to treat BRAF V600E-positive melanoma and BRAF V600E-positive non-small cell lung cancer.

Subscribe for full text news in your inbox